Electronic Harm Reduction Treatment for Alcohol
Launched by UNIVERSITY OF WASHINGTON · Nov 19, 2024
Trial Information
Current as of July 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new digital treatment program called eHaRT-A, which aims to help people who are experiencing homelessness and struggling with alcohol use disorder (AUD). The goal is to see if this online program can reduce alcohol-related harm and improve the quality of life for participants better than the standard services offered at Housing First facilities, which provide stable housing and support.
To participate in this trial, you need to be at least 21 years old, speak English fluently, and currently be living in a Housing First program. You should also have been drinking alcohol in the past two weeks and meet specific criteria for alcohol use disorder. Participants can expect to engage with the digital treatment and receive support, all while living in a safe and stable environment. This trial is currently recruiting, and everyone is welcome to apply, regardless of gender.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Being at least 21 years of age
- • Speak English fluently
- • Currently a registered client at one of the Housing First sites
- • Currently drinking (has used alcohol in the past 2 weeks)
- • Meeting criteria for "current" (e.g., past-year) AUD according to the Diagnostic and Statistical Manual of Mental Health Disorders, Fifth Edition (determined as scoring \>= 2 on the SCID-5-CV)
- Exclusion Criteria:
- • Enrollment in any related treatment studies (including studies by this research team)
- • Refusal or inability to consent
- • Constituting a risk to the safety and security of residents or staff
About University Of Washington
The University of Washington (UW) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a robust network of interdisciplinary teams, UW fosters collaboration among top-tier researchers, clinicians, and healthcare professionals, aiming to translate scientific discoveries into impactful treatments and interventions. The university is dedicated to ethical research practices and participant safety, ensuring rigorous adherence to regulatory standards in all clinical trials. Through its state-of-the-art facilities and extensive expertise, UW strives to address pressing health challenges and improve patient outcomes on a local and global scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seattle, Washington, United States
Patients applied
Trial Officials
Tessa Frohe, PhD
Principal Investigator
University of Washington
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported